因果推断提示卵巢低反应者采用拮抗剂方案与短效长方案结局相似
该回顾性研究基于美国辅助生殖技术临床结局报告系统2014至2019年自体体外受精周期数据,采用倾向性评分匹配与因果推断方法,比较卵巢低反应者使用拮抗剂方案与短效长方案的结局。结果显示,预测低反应者(抗苗勒管激素<0.5)首次周期拮抗剂方案累积活产率为14.2%(95%CI 13.6%,14.8%),短效长方案为13.6%(95%CI 12.4%,14.8%);第二周期中两种方案转换或维持的累积活产率改善也相似。结论认为卵巢低反应者首次及第二周期采用拮抗剂方案与短效长方案结局相似。
要点
- 预测低反应者首次周期拮抗剂方案累积活产率14.2%,短效长方案13.6%。
- 第二周期拮抗剂转拮抗剂组累积活产率平均改善13.9%,拮抗剂转短效长方案组14.4%。
- 短效长方案转拮抗剂组累积活产率平均改善10.4%,短效长方案转短效长方案组9.0%。
核心结论
- 卵巢低反应者首次及第二周期采用拮抗剂方案与短效长方案结局相似。
研究设计与样本
- 回顾性研究,数据来自美国辅助生殖技术临床结局报告系统2014至2019年自体体外受精周期。
- 研究对象为美国接受自体体外受精周期且使用短效长方案或拮抗剂方案的患者。
主要发现
- 倾向性评分匹配后,预测低反应者(抗苗勒管激素<0.5)首次周期拮抗剂方案累积活产率为14.2%(95%CI 13.6%,14.8%),短效长方案为13.6%(95%CI 12.4%,14.8%)。
- 第一周期低反应(获卵数<4)后第二周期,拮抗剂转拮抗剂组累积活产率平均改善13.9%(95%CI 12.1%,15.6%),拮抗剂转短效长方案组平均改善14.4%(95%CI 10.9%,18.3%)。
- 短效长方案转拮抗剂组累积活产率平均改善10.4%(95%CI 6.6%,14.5%),短效长方案转短效长方案组平均改善9.0%(95%CI 5.1%,13.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To use causal inference to investigate whether the flare or antagonist protocol is better for poor responders going through controlled ovarian stimulation. DESIGN: A retrospective study. SETTING: Retrieval cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. PATIENTS: Patients in the United States underwent autologous in vitro fertilization cycles from 2014 to 2019 using either the flare or antagonist protocol. INTERVENTION: Not applicable. MAIN OUTCOME MEASURE: Primary outcomes included oocytes retrieved, fertilized oocytes (2PNs), blastocysts, the cumulative live birth rate (CLBR), and cycle cancelation rate. RESULTS: After propensity score matching, patients with a predicted poor response (antimüllerian hormone, <0.5) on their first in vitro fertilization cycle had similar outcomes on the antagonist protocol (CLBR of 14.2%, 95% confidence intervals [CIs]: 13.6%, 14.8%) compared with flare (CLBR of 13.6%, 95% CIs: 12.4%, 14.8%). We evaluated patients undergoing a second cycle after having a poor response (<4 oocytes retrieved) on their first cycle. Patients in the antagonist-to-antagonist group had a similar change in outcomes between the first and second cycles (average CLBR improvement of 13.9%, 95% CIs: 12.1%, 15.6%) compared with the antagonist-to-flare group (average CLBR improvement of 14.4%, 95% CIs: 10.9%, 18.3%). In addition, patients in the flare-to-antagonist group had a similar change in outcomes between the first and second cycles (average CLBR improvement of 10.4%, 95% CIs: 6.6%, 14.5%) compared with the flare-to-flare group (average CLBR improvement of 9.0%, 95% CIs: 5.1%, 13.4%). CONCLUSION: Poor responders have similar outcomes on an antagonist protocol compared with a flare protocol for both the first and second cycles.
引用
- Murillo F, Fanton M, Baker VL, et al. Causal inference indicates that poor responders have similar outcomes with the antagonist protocol compared with flare. Fertil Steril. 2023. PMID: 37044308. doi:10.1016/j.fertnstert.2023.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。